Citations

Showing 10 of 108094 citations.

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, Robert I. , Bischoff, Lindsay , Ball, Douglas W., Bernet, Victor , Blomain, Erik , Busaidy, Naifa L. , Campbell, Michael J. , Dickson, Paxton V. , Ehya, Hormoz, Guo, Theresa , Holt, Shelby , Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Mandel, Susan J., McIver, Bryan, Raeburn, Christopher D., Rezaee, Rod , Roth, Mara Y. , Scheri, Randall P., Sipos, Jennifer A. , Wang, Thomas N., Wirth, Lori J. , Cassara, Carly J., Darlow, Susan, Haddad, Robert , Duh, Quan‐Yang , Goldner, Whitney Sears , Haymart, Megan R. , Iagaru, Andrei H. , Markovina, Stephanie T. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 925-951

10.6004/jnccn.2022.0040 | PMID 35948029 Get It

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).
Peripheral blood mononuclear cell phenotype and function are maintained after overnight shipping of whole blood
Johnson, Renee K., Overlee, Brittany L., Sagen, Jessica, Howe, Charles L.

Mayo Clinic

No container title available | August 10, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1933520/v1 Get It

Abstract Same day processing of biospecimens such as blood is not always feasible, which presents a challenge for research programs seeking to study a broad population or to characterize patients with rare diseases. Recruiting sites may not be equipped to process blood samples and variability in timing and technique employed to isolate peripheral blood mononuclear cells (PBMCs) at local sites may compromise reproducibility across patients. One solution is to send whole blood collected by routine phlebotomy via overnight courier to the testing site under ambient conditions. Determining the impact of shipping on subsequent leukocyte responses is a necessary prerequisite to any experimental analysis derived from transported samples. To this end, whole blood was collected from healthy control subjects and processed fresh or at 6, 24 and 48 hours after collection and handling under modeled shipping conditions. At endpoint, whole blood was assessed via a complete blood count with differential and immunophenotyped using a standardized panel of antibodies [HLADR, CD66b, CD3, CD14, CD16]. PBMCs and neutrophils were isolated from whole blood and subjected to ex vivo stimulation with lipopolysaccharide and heat-killed Staphylococcus aureus. Stimulated release of cytokines and chemokines was assessed by cytometric bead array. RNA was also isolated from PBMCs to analyze transcriptional changes induced by shipping. The complete blood count with differential revealed that most parameters were maintained in shipped blood held for 24 hours at ambient temperature. Immunophenotyping indicated preservation of cellular profiles at 24 hours, although with broadening of some populations and a decrease in CD16 intensity on classical monocytes. At the transcriptional level, RNAseq analysis identified upregulation of a transcription factor module associated with inflammation in unstimulated PBMCs derived from whole blood shipped overnight. However, these changes were limited in both scale and number of impacted genes. Ex vivo stimulation of PBMCs further revealed preservation of functional responses in cells isolated from shipped blood held for 24 hours at ambient temperature. However, neutrophil responses were largely abrogated by this time. By 48 hours neither cell population responded within normal parameters. These findings indicate that robust immunophenotyping and PBMC stimulated response profiles are maintained in whole blood shipped overnight and processed within 24 hours of collection, yielding results that are representative of those obtained from the sample immediately following venipuncture. This methodology is feasible for many patient recruitment sites to implement and allows for sophisticated immunological analysis of patient populations derived from large geographic areas. With regard to rare disease research, this meets a universal need to enroll patients in sufficient numbers for immunoprofiling and discovery of underlying pathogenic mechanisms.
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Bauer, Sebastian , Jones, Robin L. , Blay, Jean‐Yves , Gelderblom, Hans , George, Suzanne , Schöffski, Patrick , Mehren, Margaret von , Kang, Yoon‐Koo , Razak, Albiruni Abdul , Attia, Steven , Cesne, Axel Le , Su, Ying , Meade, Julie, Wang, Tao , Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , von Mehren, Margaret , Kang, Yoon-Koo , Trent, Jonathan , Attia, Steven , Le Cesne, Axel , Su, Ying , Ruiz-Soto, Rodrigo , Heinrich, Michael C , Blay, Jean-Yves , Jones, Robin L , Gelderblom, Hans , George, Suzanne , Bauer, Sebastian , Zalcberg, John , Trent, Jonathan C. , Heinrich, Michael C.

Mayo Clinic

Journal of Clinical Oncology | August 10, 2022 | Volume: 40 | Issue: 34 | Pages: 3918-3928

10.1200/jco.22.00294 | PMID 35947817 Get It

PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously treated with imatinib (INTRIGUE, ClinicalTrials.gov identifier: NCT03673501 ). PATIENTS AND METHODS Random assignment was 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off) and stratified by KIT/ platelet-derived growth factor α mutation and imatinib intolerance. The primary end point was progression-free survival (PFS) by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included objective response rate by independent radiologic review, safety, and patient-reported outcome measures. RESULTS Overall, 453 patients were randomly assigned to ripretinib (intention-to-treat [ITT], n = 226; KIT exon 11 ITT, n = 163) or sunitinib (ITT, n = 227; KIT exon 11 ITT, n = 164). Median PFS for ripretinib and sunitinib ( KIT exon 11 ITT) was 8.3 and 7.0 months, respectively (hazard ratio, 0.88; 95% CI, 0.66 to 1.16; P = .36); median PFS (ITT) was 8.0 and 8.3 months, respectively (hazard ratio, 1.05; 95% CI, 0.82 to 1.33; nominal P = .72). Neither was statistically significant. Objective response rate was higher for ripretinib versus sunitinib in the KIT exon 11 ITT population (23.9% v 14.6%, nominal P = .03). Ripretinib was associated with a more favorable safety profile, fewer grade 3/4 treatment-emergent adverse events (41.3% v 65.6%, nominal P < .0001), and better scores on patient-reported outcome measures of tolerability. CONCLUSION Ripretinib was not superior to sunitinib in terms of PFS. However, meaningful clinical activity, fewer grade 3/4 treatment-emergent adverse events, and improved tolerability were observed with ripretinib.
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Flaig, Thomas W. , Abern, Michael, Agarwal, Neeraj , Bangs, Rick , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chan, Kevin , Friedlander, Terence W. , Greenberg, Richard E. , Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kishan, Amar U. , Kundu, Shilajit , Lele, Subodh M. , Mamtani, Ronac , Margulis, Vitaly , Michalski, Jeff M., Montgomery, Jeffrey S., Nandagopal, Lakshminarayanan , Pagliaro, Lance C. , Patterson, Anthony, Pohar, Kamal S. , Preston, Mark A. , Sexton, Wade J. , Tollefson, Matthew K. , Wright, Jonathan L. , Dwyer, Mary A., Cassara, Carly J., Gurski, Lisa A., Tollefson, Matthew, Spiess, Philippe E. , Agarwal, Neeraj , Chang, Sam S. , Mian, Omar Y. , Parikh, Mamta , Plimack, Elizabeth R. , Richards, Kyle A. , Siefker-Radtke, Arlene Odelia , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 866-878

10.6004/jnccn.2022.0041 | PMID 35948037 Get It

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Peripheral tau as a biomarker for neurodegenerative diseases: is life on Earth, life on Mars?
Dugger, Brittany N. , Harvey, Danielle , Beach, Thomas G. , Dugger, Brittany N , Harvey, Danielle J , Adler, Charles H.

Mayo Clinic

Brain | August 10, 2022 | Volume: 145 | Issue: 8 | Pages: 2629-2631

10.1093/brain/awac281 | PMID 35947169 Get It

This scientific commentary refers to ‘Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies’ by Vacchi et al. (https://doi.org/10.1093/brain/awac161).
Heterozygous NOTCH1 Variants Cause CNS Immune Activation and Microangiopathy
Helman, Guy , Zarekiani, Parand , Tromp, Samantha A. M., Andrews, Ashley , Bonkowsky, Joshua L. , Chassevent, Anna , Giorgio, Elisa , Pippucci, Tommaso , Wei, Shen, Smith‐Hicks, Constance , Vaula, Giovanna , Schimmel, Mareike , Vollert, Kurt, Shimizu, Fumitaka , Kanda, Takashi , Lynch, Matthew , Roscioli, Tony , Taft, Ryan J. , Simons, Cas , Bugiani, Marianna , Shen, Wei , Bonkowsky, Joshua L , Willemsen, Michèl A A P , Shimizu, Fumitaka , van der Knaap, Marjo S , Shen, Wei , Giorgio, Elisa , Simons, Cas , Botto, Lorenzo D. , Kuijpers, Taco Willem , Knaap, Marjo S. van der

Mayo Clinic

Annals of Neurology | August 10, 2022 | Volume: 92 | Issue: 5 | Pages: 895-901

10.1002/ana.26477 | PMID 35947102 Get It

NOTCH1 belongs to the NOTCH family of proteins that regulate cell fate and inflammatory responses. Somatic and germline NOTCH1 variants have been implicated in cancer, Adams‐Oliver syndrome, and cardiovascular defects. We describe 7 unrelated patients grouped by the presence of leukoencephalopathy with calcifications and heterozygous de novo gain‐of‐function variants in NOTCH1. Immunologic profiling showed upregulated CSF IP‐10, a cytokine secreted downstream of NOTCH1 signaling. Autopsy revealed extensive leukoencephalopathy and microangiopathy with vascular calcifications. This evidence implicates that heterozygous gain‐of‐function variants in NOTCH1 lead to a chronic central nervous system (CNS) inflammatory response resulting in a calcifying microangiopathy with leukoencephalopathy. ANN NEUROL 2022;92:895–901
Knee Injuries and Associated Risk Factors in National Basketball Association Athletes
Morikawa, Landon , Brinkman, Joseph C. , Ring, David , Chhabra, Anikar , Chhabra, Anikar , Tummala, Sailesh V , Tummala, Sailesh V. , Economopoulos, Kostas J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | August 10, 2022 | Volume: 4 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2022.06.009 | PMID 36312719 Get It

Purpose To determine structural knee injury rates and to identify risk factors and the number of games missed associated with these injuries in National Basketball Association (NBA) players from the 2015 to 2020 seasons. Methods Publicly available player records of active NBA players between the 2015 and 2020 seasons (excluding the shortened 2019 season) were reviewed to identify players with a knee injury associated with missing one or more games. Player demographics, anthropometric measurements, statistics, injury characteristics, and history of other lower‐extremity injuries were recorded. We sought factors associated with having a structural knee injury in bivariate analysis and multivariable logistic regression. Negative binomial regression was conducted to evaluate factors associated with the total number of games missed. Results Two hundred twelve players (of 1,011, 21%) sustained a structural knee injury. Accounting for potential confounders, having a structural knee injury was associated with more minutes per game played (odds ratio [OR] 1.1; 95% confidence interval [CI] 1.0‐1.2; P = .002), a greater usage rate (OR 1.1; 95% CI 1.0‐1.2; P = .004), and a lower player efficiency rating (OR 0.94; 95% CI 0.89‐1.0; P = .041). A greater number of missed games was associated with more minutes per game (regression coefficient [RC] 0.065; 0.028‐0.10; P = .001), fewer points per game (RC –0.078; –0.14 to –0.017; P = .013), and greater usage rate (RC 0.032; 0.0040‐0.060; P = .025). Conclusions Structural knee injuries occurred in 21% of players in this study with an overall rate of 5.42 injuries per 1,000 game exposures. Significant risk factors associated with injury were minutes per game, usage rate, and true shooting percentage. Player efficiency was significantly associated with a decreased risk of injury. Increased minutes per game and usage rate were significantly associated with a longer duration of game loss. Level of Evidence Level IV, case series.
Affective and Perceptual Responses During an 8-Week Resistance Training to Failure Intervention at Low vs. High Loads in Untrained Women
Anderson, Olivia K., Voskuil, Caleb C. , Byrd, M. Travis, Rickard, Alex, Bergstrom, Haley C. , McNeely, Taylor K. Dinyer, Garver, Matthew J. , Miller, William Marcus

Mayo Clinic

Journal of Strength & Conditioning Research | August 10, 2022 | Volume: 37 | Issue: 3 | Pages: 546-554

10.1519/jsc.0000000000004313 | PMID 35947512 Get It

Abstract Anderson, AlOK, Voskuil, CC, Byrd, MT, Garver, MJ, Rickard, AJ, Miller, WM, Bergstrom, HC, and Dinyer McNeely, TK. Affective and perceptual responses during an 8-week resistance training to failure intervention at low vs. high loads in untrained women. J Strength Cond Res 37(3): 546–554, 2023—This study examined the effects of resistance training (RT) to failure on the perceptual and affective responses, intent-to-continue RT to failure in a self-initiated session, and affect-intent relationship. Twenty-three untrained women (mean ± SD : age 21.2 ± 2.2 years; height 167 ± 5.7 cm; body mass, 62.3 ± 16.2 kg) completed an 8-week, full-body RT to failure intervention at a low (30% 1RM; n = 11) or high (80% 1RM; n = 12) load. The Borg’s rating of perceived exertion (RPE) scale was used to assess the acute (aRPE) and session (sRPE) RPE immediately after repetition failure and each training session, respectively. Immediately, 15-minute, and 60-minute postsession affective responses were assessed using the feeling scale (FS; −5 to +5), and intent to continue to RT was assessed on a scale of 0–100% intention. During week 4 (W4) and week 8 (W8), aRPE (W4: 18 ± 2, W8: 18 ± 2; p ≤ 0.032) and sRPE (W4: 17 ± 2, W8: 18 ± 1; p ≤ 0.018) were greater than that during week 1 (W1; aRPE: 17 ± 2; sRPE: 16 ± 2). The FS responses increased from immediately to 60-minute postsession during W4 ( p ≤ 0.019) and W8 ( p ≤ 0.049). The correlation between affect and intent-to-continue RT increased from W1 ( r = 0.416) to W8 ( r = 0.777). Regardless of load, untrained women reported similar perceptual, affective, and intention responses. These variables should be considered to improve RT program adoption and adherence in women.
From What We Are Doing to Why: Describing RIME’s Core Values
Young, Meredith , Zaidi, Zareen , Balmer, Dorene F. , Hunderfund, Andrea N. Leep , Schumacher, Daniel J.

Mayo Clinic

Academic Medicine | August 10, 2022 | Volume: 97 | Issue: 11S | Pages: S1-S3

10.1097/acm.0000000000004901 | PMID 35947485 Get It